N-acetylcysteine (NAC) ( DrugBank: Acetylcysteine, N-acetylcysteine )

3 diseases

ID	Disease name (Link within this page)	Number of trials
34	Neurofibromatosis	1
51	Scleroderma	1
299	Cystic fibrosis	1

34. Neurofibromatosis

Clinical trials : 137 / Drugs : 213 - (DrugBank : 76) / Drug target genes : 87 - Drug target pathways : 200

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04481035 (ClinicalTrials.gov)	January 15, 2019	14/4/2020	Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1	Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1	Neurofibromatosis 1	Drug: N-acetylcysteine (NAC);Other: Placebo	Children's Hospital Medical Center, Cincinnati	NULL	Active, not recruiting	8 Years	16 Years	All	5	Phase 2	United States

Clinical trials : 523 / Drugs : 608 - (DrugBank : 156) / Drug target genes : 114 - Drug target pathways : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00428883 (ClinicalTrials.gov)	January 2007	29/1/2007	High Dose Intravenous N-Acetylcysteine Versus Iloprost for Early, Rapidly Progressive Diffuse Systemic Sclerosis	Rare Disease With Microvascular Involvement: High Dose Intravenous N-Acetylcysteine Versus Iloprost for Early, Rapidly Progressive Diffuse Systemic Sclerosis	Scleroderma, Diffuse	Drug: N-acetylcysteine (NAC)	Università Politecnica delle Marche	NULL	Recruiting	18 Years	80 Years	Both	45	Phase 2/Phase 3	Italy

Clinical trials : 1,696 / Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00809094 (ClinicalTrials.gov)	November 2008	15/12/2008	NAC Phase IIB: A Multi-Center, Phase IIB, Randomized, Placebo-controlled, Double-Blind Study Of The Effects Of N-Acetylcysteine On Redox Changes and Lung Inflammation In Cystic Fibrosis Patients	A Multi-Center, Phase IIB, Randomized, Placebo-controlled, Double-Blind Study Of The Effects Of N-Acetylcysteine On Redox Changes and Lung Inflammation In Cystic Fibrosis Patients	Cystic Fibrosis	Drug: N-acetylcysteine (NAC);Drug: Placebo	Stanford University	Cystic Fibrosis Foundation Therapeutics	Completed	7 Years	N/A	All	70	Phase 2	United States